Abbreviations used: FESP, 3-(2,-[18F]fluoroethyl)spiperone FWHM, full width at half-maximum; nca, non-carrier-added PET, positron emission tomography; ROI. region of interest TLC, thin-layer chromatography.
Summary: 3-(2,-[18Fjfluoroethyl) spiperone (FESP) , a re cently developed dopamine D2-receptor binding radio pharmaceutical, was used for dynamic characterization of dopamine-receptor binding in Macaca nemestrina mon keys and humans with positron emission tomography (P ET) . FESP in vitro binding properties to the dopamine receptor (ICso = 1. 5 nM) are similar to those of spiper one. Serial PET scans in monk eys after intravenous bolus injection of FESP revealed specific radioactivity accumu lation in striatum (rich in dopamine D2-receptors) , whereas radioactivity concentration declined after 20 min in frontal cortex (serotonin receptors) and more rapidly in cerebellum (nonspecific binding) . Specific dopamine D2receptor binding was saturated with increasing concen trations of radioligand (specific activity range: 1-10,000 Ci/mmol) , was stereospecifically blocked with (+ )buta clamol (0.5 mg/k g) , and showed only partial displacement with spiperone (200 j..l. g/k g, i. v. administration 90 min after FESP injection) . From PET experiments with FESP in Alterations in the biochemical integrity of the do paminergic system (e.g., changes in receptor con centrations and/or synaptic dopamine release) have been related to the development and evolution of various neuropsychiatric disorders (e.g., schizo phrenia, Parkinson's disease, tardive dyskinesia, humans, it is possible to visualize accumulation of radio activity in striatum in a manner similar to that observed in monk eys and, ex vivo, in rodents (adult male Sprague Dawley rats) . Biochemical analyses in rat brain revealed that the activity (�90%) in striatum was unmodified FESP up to 4 h after injection. On the other hand, FESP was metabolized peripherally (rat> monk ey> human) , with only 11 % of plasma radioactivity remaining as intact FESP in rodents and 54% in humans after 2 h. Based on these interspecies scaling pharmacok inetic data, it is un equivocal that FESP peripheral metabolites do not signif icantly contribute to the accumulated radioactivity in striatal tissue. Therefore, it is concluded that FESP is suitable for the quantitative estimation of dopamine D2receptor sites using PET. Key Words: 3-(2,-[18Fjfluo roethyl) spiperone (FESP) -D opamine D2-receptors Biochemical analysis-Kinetic characterization Positron emission tomography. and Huntington's disease) and the psychomotor ef fects of drugs of abuse (Sedvall et aL, 1986) . It is not surprising, therefore, that most of the work carried out in the in vivo characterization of neurotransmit ter systems with positron emission tomography (PET) has dealt with dopamine receptor biochem istry (Barrio et aL, 1988) . Specifically, the in vivo assessment of postsynaptic dopamine D2-receptors in nonhuman primates and humans with various positron-emitting labeled radiotracers has received most of the attention (Wagner et aL, 1983; Arnett et aL, 1985a,b; Sedvall et aL, 1986; Perlmutter et aL, 1986; Satyamurthy et aL, 1986) . For a detailed ki netic characterization of the radioligand, it is gen erally accepted that the 18F label (t1/2 = 109.7 min) is preferred to lie (t1/2 = 20.4 min), but most synthesis schemes previously devised to access to 18F-Iabeled neuroleptic tracers produce either poor radiochem ical yields (Barrio et aI., 1983; Kilbourn et aI., 1984) or involve multistep reaction sequences (Shiue et aI., 1985) . Recent accumulated evidence indicates that alkylation of the amide nitrogen in spiperone with short chain alkyl groups (Burns et aI., 1984; Moerlein et aI., 1985) or even larger arylalkyl moi eties (Amlaiky and Caron, 1985) does not substan tially affect the essential binding characteristics of the parent butyrophenone neuroleptic for the dopamine D2-receptors. As a result of these obser vations, in our search for F-18-labeled butyrophe nones (Barrio et aI., 1983) with efficient in vivo bind ing properties to central dopamine D2-receptors, we recently selected 3-(2' -[18F]fluoroethyl)spiperone (FESP) as a target compound (Satyamurthy et aI., 1986) . In this work, we have characterized the basic biochemical and kinetic properties of FESP in rats, nonhuman primates (Macaca nemestrina), and hu mans. We have also developed a double-injection technique for the in vivo quantitative assessment of dopamine D2-receptors in nonhuman primates (Huang et aI., 1989) .
MATERIALS AND METHODS

Chemistry
Multimillicurie amounts (>60 mCi) of non-carrier added (nca) FESP were routinely produced in a one-step, one-pot reaction from radiolabeled fluoride ion and the corresponding 2' -substituted alk ylspiperone derivatives . The chemical and radio chemical purity of the final product was higher than 99%, with a specific activity of 2-10 Ci/J.Lmol. For lower spe cific activity experiments, dilutions with authentic FESP were performed. Non carrier-added FESP suffers radiolytic decomposition in 0.9% saline but is stable in alcoholic solvents. Therefore, all studies reported in this work were performed immediately (typically within 15 min) after reconstitution of FESP in 0.9% saline and ster ilization (Gelman Acrodisc filter, 0.22 J.Lm) . Similar radi olytic decomposition was observed with [18Fl-N-methyl spiperone (MacGregor et a!., 1987) .
In vitro binding
The in vitro affinities of 2' -substituted alk ylspiperone derivatives (Table I) were determined by standard recep tor-binding techniques . In brief, rat striata were dissected, homogenized in 30 volumes of ice cold 0.25M sucrose, and the homogenate centrifuged at 3,000 g. The crude supernatant fraction was centrifuged at 15,000 g to isolate the mitochondrial fraction and sub sequently ultracentrifuged at 100,000 g. The pellet was resuspended in 50 mM Tris buffer (pH 7.6) and stored at 4°C. The binding of [ 3 Hlspiperone was determined by the incubation of membrane aliquots with various concentra tions of alk ylspiperone derivatives (0.01 to 100 nM) at Kiesewetter et aI. , 1986; 0. 67, Welch et aI. , 1988) are in agree ment with these data. All other compounds tested are either starting materials or hydrolysis products (X = OH) in the syn thesis of FESP (Satyamurthy et aI. , 1986 (Satyamurthy et aI. , , 1989 .
37°C for 15 min. When the incubations were complete, the assay mixture was filtered under vacuum through glass filters and rinsed with cold (4°C) Tris buffer (pH 7.6). Nonspecific binding of [ 3 Hlspiperone was deter mined in the presence of (+ )butaclamol (100 J.LM). The filters were placed in scintillation vials and dispersed in 10 ml of Liquiscent and the radioactivity measured in a Beck man LS 330 scintillation counter. The IC50 values for the various 2' -substituted spiperone derivatives were estimated graphically.
In vivo distribution in rats
The in vivo distribution of FESP was determined in male Sprague-Dawley rats weighing 250-300 g. Non carrier-added FESP (300-500 J.LCi) was injected via the tail vein in restrained rats. At various time intervals after the intravenous injection of the radiotracer, the animals were killed and samples of tissues were tak en and stored in liquid nitrogen before counting. All measured radioac tivities were corrected for back ground, physical decay, and counting efficiency.
In vivo autoradiographic procedures
Male Sprague-Dawley rats (250-300 g) were anesthe tized (pentobarbital, 40 mg/k g) and the femoral vein and femoral artery were cannulated towards the heart. After a 2-4 h recovery period, labeled Hlspiperone; Amersham, 21 Ci/mmol; 200 J.LCi in 0.3 ml of 0.9% saline) or nca FESP (2-10 Ci/J.Lmol; 4. 0 mCi in 0.3 ml of 0.9% saline) was administered via the venous can nula. The animals were killed at 1 h after injection, the brains quick ly removed, and frozen in pulverized dry ice. Twenty to 40 J.Lm sections were obtained for the frozen brains. Dried sections were placed in contact with the emulsion layer of x-ray film (LKB ultrafilm for [ 3 H;
Kodak NMC x-ray film for 18F) inside a spring-loaded x-ray cassette. The films were developed after approxi mately 5 week s of exposure for 3 H or after three half-lives of exposure for 18F.
Local biochemical assays and kinetic analysis in rat brain tissue Non-carrier-added FESP (300 !-lCi) was injected via the tail vein into male Sprague-Dawley rats (250-300 g) fed ad li bitum. The animals were killed at various times after injection, and striata, cerebellum, and frontal cortex were immediately removed. The separated brain tissues were rapidly homogenized in normal saline (1 ml) , extracted with diethyl ether (2 ml) by vigorously vortexing in tightly capped test tubes for 2 min, and subsequently centrifuged at 1,300 g for 15 min. The ether layer was separated and evaporated under a gentle stream of nitrogen at room temperature. The residue was dissolved in a minimum amount of dichloromethane (25-50 !-ll) and the solution was analyzed by radio-thin layer chromatography (TLC) (silica gel plates; 9: 1 CHCI 3 :CH 3 0H; Berthold model LB 2832 TLC analyzer) . The extraction efficiency of FESP by this procedure was found to be >97%. Only a mini mum amount of metabolites were extracted into the ether layer. However, the radio-TLC conditions employed well separated the polar metabolites (Rf = 0. 1-0.2) from FESP (Rf = 0.38). Therefore, knowing the amount of FESP in the ether layer, and the initial total activity in tissue, the fraction of activity in tissue that is due to either FESP or its metabolites could be calculated. All determi nations were performed at least in triplicate.
Biochemical assays in arterial plasma (rodents,
monkeys, and humans)
Male Sprague-Dawley rats (250-300 g) were cannulated as described ab ove (in vivo autoradiographic proce dures) . In Macaca nemestrina monk eys (6-9 kg), arterial blood sampling was performed by cannulation of the fem oral artery. A second cannula was inserted into the op posite femoral vein for radiotracer injection. Human sub jects had a peripheral intravenous line placed in an upper extremity. Radial artery catheterization was performed for blood sampling. After intravenous injection of nca FESP (300 !-lCi in rodents, 5 mCi in monk eys, and 5-10 mCi in humans) , a series of arterial blood samples was tak en and, after centrifugation, plasma radioactivity con centrations were determined (arterial input function) . AI iquots of plasma (0.25-1.0 ml) ob tained at selected times were extracted with diethyl ether (1.0-2.0 ml) , and the fraction of FESP and its metabolites determined as indi cated ab ove for brain tissue in rodents. Extraction effi ciency of FESP by this procedure was >98%.
Tomographic kinetic analysis in monkey brain
Macaca nemestrina monk eys weighing 6-9 kg were anesthetized with 15 mg/k g of ketamine administered in travenously at least 2 h before radiotracer injection. An endotracheal tube was inserted, and the animal later maintained under barbiturate anesthesia (12 mg/k g/h) . Different monk eys were used in saturation experiments to preclude possible long-term effects of the pharmaco logical doses of FESP used. The same monk ey was used as a control for the ( + )butaclamol experiment. The pos itron emission tomograph used for these studies was the NeuroECAT (Hoffman et aI. , 1983 ) operated in the high resolution mode ("septa in, " "shields in") . The animal J Cereb Blood Flow Metab, Vol. 9, No. 6, 1989 was positioned in the supine position with the gantry in clined 18° (frontal end tilted superiorly) relative to the cantomeatal plane. Tomographic slices, therefore, in cluded orbital structures, striatum, and cerebellum. For each study, the monk ey was either injected intravenously with FESP (3.5-5.0 mCi) , with specific activities ranging from 1 to 10,000 Ci/mmol (for saturation experiments) or pre loaded with 0.5 mg/k g ( + )butaclamol 1 h before injec tion of nca FESP. Brain scans were accumulated in a dynamic mode with 90 s scans for the first 15 min, fol lowed by 5 min scans for up to 60 min. Subsequently, 10 min scans were ob tained throughout the remainder of the experiment. Blood sampling for determination of arteria! input function and metabolite analysis was performed throughout the tomographic experiment (B ahn et aI. , 1989) .
The PET images were reconstructed with a medium resolution filter of the NeuroECAT scanner with a result ant spatial imaging resolution of 0.95 cm full width at h::: lf-maximum (FWHM). Pixel values in the tomographic images based on count rates were calibrated to values expressed in !-lCi/cm 3 . Calibration was performed by scanning a cylinder phantom with a known concentration of 18F. The well counter used for radioactivity measure ments in plasma was calibrated simultaneously. Regions of interest (ROls) were drawn on the PET images to de fine the regions of striatum and cerebellum (B ahn et aI. , 1989) . These ROls were applied to all images of a study and time-activity curves of 18F in the separately defined tissue regions were then ob tained. The locations of the corpus striatum and cerebellum within the brain were ver ified by analytical correlates with head sections in mon key brain atlas (Hartman and Strauss, 1933) . The ROI values ob tained were not corrected for partial volume effects.
RESULTS
Specific binding
Initial evidence that in vivo FESP binding in volved specific receptors was inferred from its re gional localization in rat brain autoradiography ex periments ( Fig. 1 ). After intravenous administra tion, the tracer accumulated in areas rich in dopamine-(corpus striatum, nucleus accumbens, and olfactory tubercles) and serotonin-(frontal cor tex) receptor densities, which is in agreement with the previously described behavior of eH]spiperone (Kuhar et aI., 1978) . Moreover, with caudate mem brane preparations, FESP has in vitro binding prop erties similar to spiperone (Table 1) , which agrees with the in vitro binding affinities of other flu oro alkylspiperones (Welch et aI., 1988) .
Necessary determinants of FESP receptor bind ing in vivo are, however, (a) binding saturation with increasing concentrations of radioligand (Fig. 2) , and particularly (b) the isomeric stereospecificity shown by close congeners of the radiotracer with high affinity for the receptor site (Laduron, 1988) . From a study on the preloading effects of ( + )bu taclamol (0.5 mg/kg), a substance that exhibits con- siderable specificity for neuroleptic sites (Seeman, 1981) , we have observed a complete suppression of the preferential accumulation of FESP in striatal tissue with kinetics similar to that of cerebellum ( Fig. 3 ). On the other hand, incomplete postbinding displacement of FESP striatal activity was ob served in monkeys after administration of saturat ing concentration of spiperone (200 j.1g/kg) ( Fig. 4) . brain radioactivity in rats after intravenous injec tion of FESP, also exemplifies the preferential bind ing of FESP to areas rich in dopamine receptors. Influx of the radioactive tracer into corpus striatum, cerebral cortex, and cerebellum was similar during the first few minutes. After the initial peak, both cerebellar and frontal cerebral cortex activities de clined, albeit at different rates, while that of striatal tissue increased for up to 4 h. At this time, the ratio of striatal activity to FESP activity in plasma was about 30. Also, excellent kinetic definitions of spe cific vs. nonspecific binding areas were obtained in humans with the following striatum:cerebellum ra tios: 10 min, 1.3; 30 min, 2.0; 1 h, 3.3; 2 h, 6.0; 3 h, 7. 1 (Fig. 6 ). 
Central metabolism
For identification of the chemical species contrib uting to brain activity, we performed chemical anal ysis in rat brain (Table 2) . Approximately 95% of the total striatal radioactivity at 1 h and almost 90% at 4 h was authentic FESP, in agreement with pre liminary evidence obtained by similar procedures (Barrio et aI., 1987; Coenen et aI., 1987) . Whereas only 5-10% of the total radioactivity in rat striatal tissue was not extractable, that percentage was higher in brain tissue with low dopamine D2receptor densities. A similar trend has been ob served with various positron-emitting labeled neu roleptics (Table 2) . Table 3 and Fig. 7 exemplify the effect of inter species scaling in the peripheral metabolism of FESP. It is apparent from the data that rodents me tabolize FESP peripherally more rapidly than mon keys and humans. For example, at 120 min, only 11 % of the plasma radioactivity can be identified as authentic FESP in rodents, but this proportion in creases to 54% in humans. Moreover, inspection and analysis of the total activity in the arterial plasma as a function of time for FESP in rodents ( Fig. 7 A) , monkeys (Fig. 7B) , and humans ( Fig. 7C) immediately reveals the effect of species differ ences. Specifically, after bolus injection of FESP, only in rodents did the total arterial activity in crease after its initial low level observed at 5 min, doubling its value at 3 h. This reflects a rapid for- Table 2) .
Peripheral metabolism: interspecies scaling
mation of FESP peripheral metabolites with a slow blood clearance. However, as expected, labeled FESP rapidly declines to a low steady state in all three animal species. The preferential accumulation of radioactivity in the enterohepatic system after intravenous admin-8r---------------C -a u -d -a -le ------.-· · · -· · -·· -· ·· -· · · -· · -· · � · · � · ·� . FIG. 6. Time course of caudate and cerebellar radioactivity determined from PET in humans after intravenous bolus in jection of nca FESP (5-10 mCi). PET scanning was started coincident with injection and was continued for a total of 420 min. Full studies consisted of a sequence of ten 90 s images, nine 5 min images, twelve 10 min images, and 30 min images thereafter. For quantitative work, arterial blood samples were obtained at 12 s intervals for 2 min after injection. Thereafter, samples were obtained every min (from 2 to 5 min), and at 7, 10, 30, 60, 90, 120, 180, 240 , and 420 min for determination of time-activity curves and metabolite formation (Table 3) . istration of FESP is indicative of preferential biliary elimination (Table 4 ). No activity in bone tissue was observed in rodents, which indicated that FESP, in contrast to N-['sF]-3-fluoropropylspiperone (Welch et aI., 1988) , does not follow an in vivo defluorina tion pathway. This was confirmed with tomo graphic scans in monkeys (for up to 3 h) and hu mans (for up to 7 h), with no observable deposition of radioactivity in bone tissue with time.
DISCUSSION
Binding specificity: kinetic characterization
The introduction of 3-N[llC]methylspiperone (Wagner et aI., 1983) clearly demonstrated the value of3-N-alkylkspiperone derivatives for evaluation of central dopamine D2-receptors with PET in hu mans. Among the lsF-labeled N-alkylbutyrophe nones, we recently selected 3-(2,-['sF]fluoroethyl) spiperone (FESP) as a target compound (Satyamur- , 1986) . It has been highly significant for the present work that the synthetic approach dis covered in our laboratories based on a nucleophilic displacement with [,sF]fluoride ion resulted in an easy, one-step, one-pot multimillicurie synthesis of nca FESP (Satyamurthy et aI., 1986 (Satyamurthy et aI., , 1989 . The procedure provides an efficient, reproducible chem ical access to the positron-emitting radiotracer, and also overcomes the drawbacks that characterize many of the previous methods based on aromatic radio-fluorination (Barrio et aI., 1983; Kilbourn et aI. , 1984; Shiue et aI., 1985) . Following the first gratifying discovery that FESP binds in vivo to rat brain similarly to spiper one (Fig. 1) , we verified its in vivo binding charac teristics in primate brain (Macaca nemestrina), us ing kinetic analysis with PET (Barrio et aI., 1986; Satyamurthy et aI., 1986; Huang et aI. , 1989) . After intravenous injection, the radiotracer was rapidly transported through the blood-brain barrier due to its high hydrophobicity [log of partition coefficient (P) = 3. 48 vs. 2.67 for spiperone (Coenen et aI., 1987; Moerlein et aI., 1985) ]. Thereafter, the tracer accumulated in striatum (dopamine D2-receptors) and rapidly washed out from cerebellum, an area lacking dopaminergic terminals (Murrin and Kuhar, 1979) (Fig. 2) .
The in vivo blocking of FESP binding to striatal tissue with (+ )butaclamol is similar to that ob served with other radiolabeled neuroleptics (Arnett et aI., 1985a,b) . Since (+ )butaclamol is structurally unrelated to butyrophenone neuroleptics, this ob servation together with the anatomical localization of FESP binding and the FESP saturation kinetics in striatum (Fig. 2) provide evidence for in vivo binding of FESP to receptor domains.
This high time-dependent specific localization is a critical determinant of the utility of FESP for in
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. Arterial plasma input function (0, total radioactivity; 0 , corrected for metabolites) after intravenous injection of nca FESP (A, rat; B, monkey; C, human). Values are mean of n = 3 (rat), n = 7 (monkey), and n = 9 (human).
vivo neuroreceptor assays with PET because of the clear anatomical delineation of specific binding over a background of nonspecific distribution observed in all species studied, from rodents to humans (Bar rio et al., 1987) . This finding enables direct kinetic studies of in vivo radio ligand binding without the immediately apparent, undesired consequences of high nonspecific binding. The problems associated with high nonspecific binding have affected the ef fective tomographic use of eSF]haloperidol (Arnett et al., 1985b) . It is also apparent from Fig. 5 that striatal activity does not decline in rat brain until al least 5 h after intravenous injections of FESP, with an in vivo clearance rate (half-time) of> 10 h. This slow clear ance, analogous to that presented in vivo for [3R]spiperone (Rollt and Schubert, 1978) , provides support to the idea that radionuclides with longer half-lives (e.g., IsF vs. IIC) are better suited for a detailed analysis of in vivo neuroleptic kinetics. The slow in vivo striatal clearance of spiperone, in con trast to its rapid in vitro dissociation from receptor sites, has been recently attributed to a mechanism of dopamine-mediated receptor internalization and recycling (Chugani et al., 1988) . Such a postulate is consistent with the incomplete postbinding dis placement of FESP striatal activity in monkeys af ter administration of saturating concentrations of spiperone (200 J.Lg/kg) ( Fig. 4) . Similar results were obtained earlier with the displacement of eH]spip erone from rat brain .
Binding specificity: biochemical correlates
We have argued elsewhere (Barrio et al., 1988 ) that identification of the chemical species contrib uting to striatal activity is essential for quantitative PET studies. We therefore performed chemical analysis of the radioactivity accumulated in striatal tissue after intravenous administration of FESP. Results in rodents clearly support the premise that the high time-dependent FESP accumulation in stri atal tissue (ratio of corpus striatum/cerebellum = 8 at 4 h) is due to receptor binding, which is consis tent with the high percentage (90%) of extractable FESP from that tissue. A time-dependent brain dis tribution of background activity was observed in these rodent studies with FESP. This uniform back ground activity, similar to that observed with other radiolabeled neuroleptics (Table 2) , was not signif icant in areas rich in dopaminergic terminals (e.g., striatum). It is therefore unlikely to be a factor that could affect the specificity of the tomographic de termination in humans (e.g., Bmax, KD).
With regard to the origin of the nonextractable brain activity (Table 2) , it seems clear that cerebral metabolism of neuroleptics is improbable. In fact, several authors have reported that spiperone is met abolically stable in rodent brain (Hollt et aI., 1977; Kuhar et aI., 1978; Laduron et aI., 1978) . Similar brain metabolic stability was also predicated for most radiolabeled butyrophenone neuroleptics de spite rapid peripheral metabolism (Arnett et aI., 1985a,b) .
FESP is metabolized peripherally in mammals at a rate that is comparable with that of other buty rophenone neuroleptics (Chugani et al., 1983; Fowler et aI., 1986) . Using tritiated butyrophenone neuroleptics, Soudijn et ai. (1987) and Braun et ai. (1967) have shown in rats that oxidative N-dealkyl ation and the subsequent degradation of the buty rophenone chain to produce 3-(4-fluorobenzoyl) propionic acid, 4-fluorophenylacetic acid, and 4fluorophenylaceturic acid constitute a major meta bolic pathway for butyrophenones. In vitro studies by Marcucci et ai. (1971) have identified 4-(p-chlo rophenyl)-4-hydroxypiperidine and 4-hydroxy-4)ex, ex,ex-trifluoro-m-tolyl)piperidine as metabolites by the N-dealkylation of haloperidol and trifluperidol, respectively. Biotransformation studies of other bu tyrophenone neuroleptics (Fusaro et aI., 1976; Ta chizawa et aI., 1981; Wong et aI., 1983) indicate the fo rmation of analogous piperidino metabolites. The nonpermeability of 3-(4-[ lSF]fluorobenzoyl)pro pionic acid across the blood-brain barrier suggests that the acidic metabolites might not enter the brain (Digenis et aI., 1981) . However, little reliable infor mation is available as to the permeability of the pi peridino and other related basic metabolites into the brain, although a comparative serial study in ba boons with eSF]N-methylspiperone and N-e lC]meth ylspiperone, which could potentially produce radio active metabolites containing the triazaspiro decanone moiety, indicates that the differential kinetic effect of any metabolite delivered to the brain by plasma, if any, is small and nondetectable by PET analysis (Fowler, et aI., 1986) . Moreover, it is improbable that radiolabeled triazaspirode canone-containing FESP metabolites arising from plasma (and assuming transport into the brain) would have any binding affinity to the dopamine D2-receptor because they lack the necessary 4' -fluoro-4-aminobutyrophenone pharmacophore (Kaiser and Setler, 1981) .
As can be seen in Fig. 7 , FESP peripheral metab olism is characterized by differences in interspecies kinetics (Barrio et aI., 1987) . A mistaken view is that extrapolation of biochemical results in rodent to nonhuman primates and humans can be done without a careful quantitative correlation of inter species pharmacokinetics. If we cannot describe, organize, and categorize differences in metabolism between mammal species, we are at an immediate disadvantage in relating the results to humans for interpretation of PET studies.
We have correlated FESP pharmacokinetic pa rameters to interspecies variations of body size (Barrio, et aI., 1987) . This procedure, termed allom etry (Boxenbaum, 1982) , is particularly useful for drugs whose primary route of elimination is either biliary or renal, as is the case for FESP (Table 4) . When drug metabolism is involved, other concepts can also be elaborated and genetically correlated to total metabolism per kg of body weight (Bodding ton, 1978) . Independently of the quantitative value that one would like to give to these semiempirical correlations, it is obvious from the data that rodents metabolize drugs (e.g., FESP) more rapidly than humans. Actually, the production of peripheral FESP metabolites in rats is 1.5 times faster than in monkeys and about 6.2 times faster than in humans, as measured by the clearance half-time of arterial FESP in these species (Fig. 7 , Table 3 ). This differ ential interspecies buildup of FESP metabolites is probably due to a combination of factors, including different rates of oxidative metabolism, and renal or biliary elimination.
Since the relative rates of transport by passive diffusion across the blood-brain barrier should be dependent on relative plasma concentrations, one could conclude that, if any penetration of plasma metabolites is to occur in the brain, it will be much lower in humans than in rodents. Since 90% of the activity in rat brain striatum for up to 4 h is intact FESP (Table 3) , one could safely assume a similar occurrence in humans at least 4 h after injection of FESP. Typical FESP kinetic studies with excellent kinetic definition in humans are performed for no longer than 3 h (approximately equivalent to 30 min in rats) (striatum:cerebellum ratios in humans: 10 min, 1.3; 30 min, 2.0; 1 h, 3.3; 2 h, 6.0; 3 h, 7.1) (Fig.  6) . Further, from the relative rates of peripheral me tabolite formation in rodents, monkeys, and hu mans, it can be concluded that there is still a signif icant safety margin for increasing the length of quantitative tomographic studies beyond that pe riod.
In part due to the complexities of the nonspecific binding and metabolism of all butyrophenone neu roleptics (Table 2) , analysis techniques of tomo graphic data using cerebellum as a reference tissue (Wagner et aI., 1983; Wong et aI., 1984) have been under increasing criticism (Perlmutter et aI., 1986; Perlmutter and Raichle, 1987) . Indeed, the high hy drophobicity of butyrophenone neuroleptics com bined with a locus for ionic interactions in the mol-ecule make them primarily susceptible to heteroge neous nonspecific binding (Seeman, 1981) . This may drastically affect the accuracy of the kinetic analyses of receptor sites when cerebellum is used as reference tissue . Therefore, analysis techniques that avoid the use of reference tissues for quantitative analysis of receptor binding transform the issue of background activity in those tissues into a moot argument. CONCLUSIONS FESP appears to be a key radiotracer to study dopamine D2-neuroreceptor biochemistry and its correlation with human brain function and its dis turbances. Several important features validate this observation: (1) FESP in vivo metabolic stability in brain striatum, which permits a quantitative estima tion of its kinetic behavior for many hours; (2) its performance in in vitro competitive binding studies, in vivo rodent brain autoradiography, in vivo bind ing in rat striatum, and tomographic studies in non human primates and humans; and (3) the simplicity and reproducibility of its synthesis, which permits the preparation of multimillicurie amounts (>60 mCi) of non-carrier-added 18F-Iabeled neuroleptic. A detailed analysis of the kinetic behavior of FESP for determination of receptor density and number is provided by Huang et al. (1989) .
